Pharmacological interventions vs placebo
- Prevention of depression in adults with long‐term physical conditions 2021 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether pharmacological interventions changes acceptability ‐ drop‐outs due to adverse events: post‐intervention compared with placebo (very low certainty).
It is very uncertain whether pharmacological interventions changes acceptability ‐ drop‐outs due to any cause: post‐intervention compared with placebo (very low certainty).
It is very uncertain whether pharmacological interventions changes incidence of depression ‐ post‐intervention: 0 months compared with placebo (very low certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher partcipant assessment of success compared with placebo (moderate certainty).
Summary of Findings Table ‐ IncobotulinumtoxinA 20U probably leads to higher participant assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
Summary of Findings Table ‐ IncobotulinumtoxinA 20U probably leads to higher physician assessment of success by analysing scores and scales compared with placebo (moderate certainty).
Summary of Findings Table ‐ IncobotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher major adverse events compared with placebo (moderate certainty).
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher participant assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher physician assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher total adverse events compared with placebo (moderate certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher physician assessment of success compared with placebo (moderate certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).